Angiodynamics (ANGO) revenue and earnings history
Angiodynamics reported revenue of $320M for fiscal 2026 (year ended May 31, 2026), +9.5% on the year before, and net income of −$36.7M.
Over 16 years, from fiscal 2010 to fiscal 2026, revenue grew at a compound rate of +2.5% a year.
Revenue and net income, 17 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026ended May 31, 2026 | $320M+9.5% | −$39.9M | −$36.7M | $3.09M | $2.58M | $508K | $14M | $0 | — | $53.9M | — | 10-K/A |
| 2025ended May 31, 2025 |
The latest quarter, insider trades and fund moves: Angiodynamics (ANGO) on OQRO.
Common questions
What was Angiodynamics's revenue in fiscal 2026?
$320M for the year ended May 31, 2026, as reported in its 10-K/A filed Sep 29, 2026. That is +9.5% on fiscal 2025 ($292M).
How fast has Angiodynamics's revenue grown?
From $216M in fiscal 2010 to $320M in fiscal 2026: a compound annual growth rate of +2.5% over 16 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Where these figures come from
The SEC’s companyfacts data: every figure Angiodynamics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
